European Heart Journal Advance Access originally published online on November 23, 2008
European Heart Journal 2009 30(1):66-73; doi:10.1093/eurheartj/ehn525
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prognostic threshold levels of NT-proBNP testing in primary care
1 Department of Cardiology, Frederiksberg University Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark
2 Department of Cardiology, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark
3 Københavns Praktiserende Lægers Laboratorium, Pilestræde 65, 1112 København K, Denmark
4 Department of Cardiology, Glostrup University Hospital, Nordre Ringvej 57, 2600 Glostrup, Denmark
Received 4 August 2008; revised 22 September 2008; accepted 31 October 2008; online publish-ahead-of-print 23 November 2008.
* Corresponding author. Tel: +45 38 16 43 78, Fax: +45 38 16 43 59, Email: cor{at}dadlnet.dk
Aims: Chronic heart failure (HF) is a common condition with a poor prognosis. As delayed diagnosis and treatment of HF patients in primary care can be detrimental, risk-stratified waiting lists for echocardiography might optimize resource utilization. We investigated whether a prognostic threshold level of the cardiac peptide, NT-proBNP, could be identified.
Methods and results: From 2003–2005, 5875 primary care patients with suspected HF (median age 73 years) had NT-proBNP analysed in the Copenhagen area. Eighteen percent died and 20% had a cardiovascular (CV) hospitalization (median follow-up time: 1127 and 1038 days, respectively). In Cox proportional hazards regression models regarding NT-proBNP levels, the fourth decile (range: 83–118 pg/mL) was associated with a 90% (95% CI: 30–190, P < 0.01) increased risk for CV hospitalization and the seventh decile (range: 229–363 pg/mL) was associated with an 80% (95% CI: 20–190, P = 0.01) increased mortality risk after adjustment for age, sex, previous hospitalization, CV diseases, and chronic diseases.
Conclusion: We identified prognostic threshold levels for mortality and CV hospitalization for NT-proBNP in primary care patients suspected of HF. Our results have the potential to be used to risk-stratify waiting lists for echocardiography.
Key Words: Brain natriuretic peptide • Prognosis • Congestive heart failure • Primary care
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. C.M. Linssen, S. J.L. Bakker, A. A. Voors, R. T. Gansevoort, H. L. Hillege, P. E. de Jong, D. J. van Veldhuisen, R. O.B. Gans, and D. de Zeeuw N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population Eur. Heart J., October 23, 2009; (2009) ehp420v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Schou, U Alehagen, J P Goetze, F Gustafsson, and U Dahlstrom Effect of estimated glomerular filtration rate on plasma concentrations of B-type natriuretic peptides measured with multiple immunoassays in elderly individuals Heart, September 15, 2009; 95(18): 1514 - 1519. [Abstract] [Full Text] [PDF]
|
|